Peptides for Lyme Disease — Evidence-Based Overview

How peptide Targets Peptides for Lyme Disease

Lyme disease, caused by Borrelia burgdorferi infection, presents a complex therapeutic challenge — particularly in cases of persistent symptoms after standard antibiotic treatment, often referred to as Post-Treatment Lyme Disease Syndrome (PTLDS). The peptide approach to Lyme disease targets several aspects of the condition: direct antimicrobial activity against Borrelia, immune system modulation to address dysregulated inflammatory responses, neuroprotection against Lyme neuroborreliosis, and symptom management for the fatigue, cognitive dysfunction, and pain that characterize chronic presentations.

LL-37 is the most mechanistically interesting peptide for Lyme disease. As the only human cathelicidin antimicrobial peptide, LL-37 has documented activity against a range of bacteria and can disrupt biofilms — a proposed mechanism by which Borrelia may evade antibiotic treatment. In vitro studies have demonstrated activity of cathelicidins against spirochetes, though direct clinical evidence for LL-37 against Borrelia in human Lyme disease is absent. Thymosin Alpha-1 (Ta1) is an immune-modulating peptide with FDA-orphan-drug status that enhances dendritic cell function, T-cell maturation, and NK cell activity. Its role in Lyme disease protocols relates to restoring immune competence in patients whose immune response to Borrelia has become dysfunctional, particularly in chronic presentations where immune evasion by the spirochete is suspected.

KPV (Lys-Pro-Val) is an anti-inflammatory tripeptide derived from alpha-MSH that modulates NF-kB signaling and has been used in Lyme protocols primarily for its anti-inflammatory properties, particularly for Lyme-associated gut inflammation and neuroinflammation. BPC-157 is included in some Lyme protocols for its broad tissue-protective and anti-inflammatory effects, addressing the musculoskeletal pain, neuropathy, and GI dysfunction that commonly accompany Lyme disease. VIP (Vasoactive Intestinal Peptide) has been discussed in the context of mold illness and chronic inflammatory response syndrome (CIRS), which overlaps significantly with chronic Lyme presentations. It is critical to acknowledge that peptide use for Lyme disease is almost entirely based on mechanistic reasoning and clinical extrapolation rather than Lyme-specific clinical trials. Standard antibiotic treatment remains the evidence-based first-line therapy, and peptides should be considered experimental adjuncts rather than replacements.